(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
(CIDRAP News) Health experts who investigated Europe's first chikungunya outbreak involving transmission by local mosquitoes recently reported that cases could occur again next spring unless vigorous mosquito surveillance and eradication measures are used to control the disease in Italyand prevent its spread to other parts of Europe.
Editor's note: This is the second in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame.
(CIDRAP News) – A recent outbreak of the debilitating tropical disease known as chikungunya fever in northern Italy apparently marks the mosquito-borne infection's first foothold in Europe, according to European health authorities.
(CIDRAP News) The British pharmaceutical company GlaxoSmithKline (GSK) recently announced another major order of prepandemic H5N1 influenza vaccine from the US Department of Health and Human Services (HHS), along with plans to launch a North American clinical trial of the vaccine.
(CIDRAP News) Antibodies gleaned from four Vietnamese patients who survived H5N1 avian influenza were used successfully to prevent and treat H5N1 infection in mice, suggesting that the same approach might be useful in humans, according to a recent report by an international team of researchers.
(CIDRAP News) – The Swiss pharmaceutical company Roche announced today it is scaling back production of oseltamivir (Tamiflu) because of waning demand, and simultaneously questioned whether countries stockpiling the drug are buying enough to protect their citizens in the event of an influenza pandemic.